Repair of Rhodopsin mRNA by Spliceosome-Mediated RNA Trans -Splicing: A New Approach for Autosomal Dominant Retinitis Pigmentosa
Year: 2015
Type: article
Abstract: The promising clinical results obtained for ocular gene therapy in recent years have paved the way for gene supplementation to treat recessively inherited forms of retinal degeneration. The situation is more complex for dominant mutations, as the toxic mutant gene product must be removed. We used spliceosome-mediated RNA trans-splicing as a strategy for repairing the transcript of the rhodopsin gene, the gene most frequently mutated in autosomal dominant retinitis pigmentosa. We tested 17 different molecules targeting the pre-mRNA intron 1, by transient transfection of HEK-293T cells, with subsequent trans-splicing quantification at the transcript level. We found that the targeting of some parts of the intron promoted trans-splicing more efficiently than the targeting of other areas, and that trans-splicing rate could be increased by modifying the replacement sequence. We then developed cell lines stably expressing the rhodopsin gene, for the assessment of phenotypic criteria relevant to the pathogenesis of retinitis pigmentosa. Using this model, we showed that trans-splicing restored the correct localization of the protein to the plasma membrane. Finally, we tested our best candidate by AAV gene transfer in a mouse model of retinitis pigmentosa that expresses a mutant allele of the human rhodopsin gene, and demonstrated the feasibility of trans-splicing in vivo. This work paves the way for trans-splicing gene therapy to treat retinitis pigmentosa due to rhodopsin gene mutation and, more generally, for the treatment of genetic diseases with dominant transmission.
Source: Molecular Therapy
DOI: 10.1038/mt.2015.11
Institutions: Centre National de la Recherche Scientifique, Institut de la Vision, Inserm, Sorbonne Université, Université Pierre-et-Marie-Curie, Centre de Recherche en Myologie, Université Paris-Sud, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Paris-Saclay, Institut d'Imagerie Biomédicale, CEA Paris-Saclay - Etablissement de Fontenay-aux-roses, Laboratoire des Maladies Neurodégénératives, Direction des Sciences du Vivant, Molecular Imaging Research Center, Université de Versailles Saint-Quentin-en-Yvelines, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, Fondation Ophtalmologique Adolphe de Rothschild, University College London
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funder: Agence Nationale de la Recherche
Awards: G4031799020, G5551520971
OpenAlex ID: W1975297325
